These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28236795)

  • 41. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
    Staatz CE; Taylor PJ; Lynch SV; Tett SE
    Liver Transpl; 2004 Apr; 10(4):506-12. PubMed ID: 15048793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.
    Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the long-term efficacy and safety of generic Tacrobell with original tacrolimus (Prograf) in kidney transplant recipients.
    Son SY; Jang HR; Lee JE; Yoo H; Kim K; Park JB; Kim SJ; Oh HY; Huh W
    Drug Des Devel Ther; 2017; 11():203-210. PubMed ID: 28138224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period.
    Ben Fredj N; Chaabane A; Chadly Z; Hammouda M; Aloui S; Boughattas NA; Skhiri H; Aouam K
    Transpl Immunol; 2013 Jun; 28(4):198-202. PubMed ID: 23608723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan.
    Takahashi K; Abe R; Usuki S; So M
    Transplant Proc; 2014; 46(2):406-10. PubMed ID: 24655975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation.
    Czubkowski P; Wierzbicka A; Socha P; Jankowska I; Pawłowska J
    Ann Transplant; 2014 Nov; 19():604-8. PubMed ID: 25409773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generics: are all immunosuppression agents created equally?
    Hauch A; John M; Smith A; Dortonne I; Patel U; Kandil E; Killackey M; Paramesh A; Lee B; Zhang R; Buell JF
    Surgery; 2015 Oct; 158(4):1049-54; discussion 1054-5. PubMed ID: 26206317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
    Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
    Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus Predose Concentration Is Associated With Hypertension in Pediatric Liver Transplant Recipients.
    Prytula A; Vandekerckhove K; Raes A; De Wolf D; Dehoorne J; Vande Walle J; De Bruyne R
    J Pediatr Gastroenterol Nutr; 2016 Dec; 63(6):616-623. PubMed ID: 26910645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge.
    Jannot M; Masson I; Alamartine E; Mariat C
    Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients.
    Naesens M; Salvatierra O; Li L; Kambham N; Concepcion W; Sarwal M
    Transplantation; 2008 Apr; 85(8):1139-45. PubMed ID: 18431234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    van Hooff J; Van der Walt I; Kallmeyer J; Miller D; Dawood S; Moosa MR; Christiaans M; Karpf C; Undre N
    Ther Drug Monit; 2012 Feb; 34(1):46-52. PubMed ID: 22249344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of tacrolimus in adult renal transplant recipients.
    Naik P; Madhavarapu M; Mayur P; Nayak KS; Sritharan V
    Drug Metabol Drug Interact; 2012; 27(3):151-5. PubMed ID: 23089531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sublingual administration of tacrolimus: current trends and available evidence.
    Doligalski CT; Liu EC; Sammons CM; Silverman A; Logan AT
    Pharmacotherapy; 2014 Nov; 34(11):1209-19. PubMed ID: 25251980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
    Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
    Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.